Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,...
Reexamination Certificate
2006-04-18
2006-04-18
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
C424S143100, C424S144100, C435S375000, C435S377000, C530S387100, C530S388220
Reexamination Certificate
active
07029674
ABSTRACT:
Disclosed are methods for downmodulating an immune response comprising contacting an immune cell with an agent that modulates the interaction between PD-1 and a PD-1 ligand (e.g., soluble forms of PD-1 or PD-1 ligand or antibodies to PD-1) to thereby modulate the immune response.
REFERENCES:
patent: 5580756 (1996-12-01), Linsley et al.
patent: 5698520 (1997-12-01), Honjo et al.
patent: 2002/0160000 (2002-10-01), Wood et al.
patent: WO 95/03408 (1995-02-01), None
patent: WO 01/14556 (2001-03-01), None
patent: WO 01/14557 (2001-03-01), None
Huang, Pharmacol. Ther., 2000, 86: 201-215.
Riley et al., Blood, 2005, 105: 13-21.
Agata, Y. et al. Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes.Int. Immunol.May 1996;8(5):765-72.
Dong, H. et al. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.Nat. Med.Dec. 1999;5(12):1365-9.
EST Database Acc. No.: AA292201; zt50f01.r1 Soares ovary tumor NbHOTHomo sapienscDNA clone IMAGE:725785 5′, mRNA sequence (1997).
EST Database Acc. No.: AA399416; zt50f01.s1 Soares ovary tumor NbHOTHomo sapienscDNA clone IMAGE:725785 3′, mRNA sequence (1997).
Freeman, G.J. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.J. Exp. Med.Oct. 2, 2000;192(7):1027-34.
Genbank Accession No. AF344424;Homo sapiensPD-1-ligand 2 protein (PDL2) mRNA, complete cds (2001).
Honjo, T.Seppukuand autoimmunity.Science.Oct. 23, 1992;258(5082):591-2.
Ishida, Y. et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.EMBO J.Nov. 1992;11(11):3887-95.
Krummel, M. F. et al. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells.J. Exp. Med.Jun. 1, 1996;183(6):2533-40.
Latchman, Y. et al., PD-L2 is a second ligand for PD-1 and inhibits T cell activation.Nat. Immunol.Mar. 2001;2(3):261-8.
Nishimura, H. et al. Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responses.Int. Immunol.Oct. 1998;10(10):1563-72.
Nishimura, H. et al. Developmentally regulated expression of the PD-1 protein on the surface of double-negative (CD4−CD8−) thymocytes.Int. Immunol.May 1996;8(5):773-80.
Shinohara, T. et al. Structure and chromosomal localization of the human PD-1 gene (PDCD1).Genomics. Oct. 1994;23(3):704-6.
Walunas, T. L. et al. CTLA-4 ligation blocks CD28-dependent T cell activation.J. Exp. Med.Jun. 1, 1996;183(6):2541-50.
Woronicz, J. et al. Death genes in T cells.Curr. Top. Microbiol. Immunol.1995;200:137-46.
Finger et al. “The human PD-1 gene: complete cDNA, genomic organization, and developmentally regulated expression in B cell progenitors.”Gene, (1997), vol. 197, pp.: 177-187.
Henry et al. “Structure and evolution of the extended B7 family.”Immunology Today, (1999), vol. 20, No. 6, pp.: 285-288.
Nishimura et al. “Developmental of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITM Motif-Carrying Immunoreceptor.”Immunity, (1999), vol. 11, pp.: 141-151.
Nishimura et al. “PD-1 Regulates Self-Tolerance To Prevent Tissue Destruction.” (1998),Journal of Investigative Dermatology, vol. 110, No. 4, p.: 477, Abstr. 25.
Nishimura et al. “Facilitation of β Selection and Modification of Positive Selection in the Thymus of PD-1-deficient Mice.”Journal of Experimental Medicine, (2000), vol. 191, No. 5, pp.: 891-897.
Vibhakar et al. “Activation-Induced Expression of Human Programmed Death-1 Gene in T-Lymphocytes.”Experimental Cell Research, (1997), vol. 232, pp.: 25-28.
Vivier et al. “Immunoreceptor tyosin-based inhibition motifs.”Immunology Today, (1997), vol. 18, pp.: 286-291.
Genbank Acession No. AF177937;Homo sapiensB7-H1 mRNA, complete cds (1999).
Swissprot No. Q13410; Butyrophilin precursor (BT), (1997).
Carreno Beatriz M.
Leonard John
Gambel Phillip
Lahive & Cockfield LLP
Mandragouras Esq. Amy E.
Ouspenski Ilia
Wyeth
LandOfFree
Methods for downmodulating immune cells using an antibody to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for downmodulating immune cells using an antibody to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for downmodulating immune cells using an antibody to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3555659